Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

A Radiosensitizing Inhibitor of HIF-1 alters the Optical Redox State of Human Lung Cancer Cells In Vitro.

Lee DE, Alhallak K, Jenkins SV, Vargas I, Greene NP, Quinn KP, Griffin RJ, Dings RPM, Rajaram N.

Sci Rep. 2018 Jun 11;8(1):8815. doi: 10.1038/s41598-018-27262-y.

2.

Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells.

Kore RA, Edmondson JL, Jenkins SV, Jamshidi-Parsian A, Dings RPM, Reyna NS, Griffin RJ.

Biochem Biophys Rep. 2018 May 2;14:104-113. doi: 10.1016/j.bbrep.2018.03.008. eCollection 2018 Jul.

3.

Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems.

Jenkins SV, Nima ZA, Vang KB, Kannarpady G, Nedosekin DA, Zharov VP, Griffin RJ, Biris AS, Dings RPM.

NPJ Precis Oncol. 2017 Sep 1;1(1):27. doi: 10.1038/s41698-017-0030-1. eCollection 2017.

4.

Consensus guidelines for the use and interpretation of angiogenesis assays.

Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, Böck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesquière B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW.

Angiogenesis. 2018 May 15. doi: 10.1007/s10456-018-9613-x. [Epub ahead of print] Review.

5.

Galectins as Molecular Targets for Therapeutic Intervention.

Dings RPM, Miller MC, Griffin RJ, Mayo KH.

Int J Mol Sci. 2018 Mar 19;19(3). pii: E905. doi: 10.3390/ijms19030905. Review.

6.

Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models.

Koonce NA, Griffin RJ, Dings RPM.

Int J Mol Sci. 2017 Dec 9;18(12). pii: E2671. doi: 10.3390/ijms18122671.

7.

Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using in vivo flow cytometry.

Koonce NA, Juratli MA, Cai C, Sarimollaoglu M, Menyaev YA, Dent J, Quick CM, Dings RPM, Nedosekin D, Zharov V, Griffin RJ.

Biochem Biophys Res Commun. 2017 Oct 21;492(3):507-512. doi: 10.1016/j.bbrc.2017.08.053. Epub 2017 Aug 16.

PMID:
28822765
8.

Modifying Dendritic Cell Activation with Plasmonic Nano Vectors.

Vang KB, Safina I, Darrigues E, Nedosekin D, Nima ZA, Majeed W, Watanabe F, Kannarpady G, Kore RA, Casciano D, Zharov VP, Griffin RJ, Dings RPM, Biris AS.

Sci Rep. 2017 Jul 14;7(1):5513. doi: 10.1038/s41598-017-04459-1.

9.

Optical imaging of radiation-induced metabolic changes in radiation-sensitive and resistant cancer cells.

Alhallak K, Jenkins SV, Lee DE, Greene NP, Quinn KP, Griffin RJ, Dings RPM, Rajaram N.

J Biomed Opt. 2017 Jun 1;22(6):60502. doi: 10.1117/1.JBO.22.6.060502.

10.

Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy.

Jenkins SV, Nedosekin DA, Miller EK, Zharov VP, Dings RPM, Chen J, Griffin RJ.

Int J Hyperthermia. 2018 Feb;34(1):19-29. doi: 10.1080/02656736.2017.1317845. Epub 2017 May 9.

11.

Further rationale for optimal combined modality treatments.

Griffin RJ, Dings RPM, Makhoul I.

Oncotarget. 2017 Apr 18;8(16):25831-25832. doi: 10.18632/oncotarget.16117. No abstract available.

12.

Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-α and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models.

Koonce NA, Quick CM, Hardee ME, Jamshidi-Parsian A, Dent JA, Paciotti GF, Nedosekin D, Dings RP, Griffin RJ.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):588-96. doi: 10.1016/j.ijrobp.2015.07.2275. Epub 2015 Jul 26.

13.

Targeting Artificial Tumor Stromal Targets for Molecular Imaging of Tumor Vascular Hypoxia.

Koonce NA, Levy J, Hardee ME, Jamshidi-Parsian A, Vang KB, Sharma S, Raleigh JA, Dings RP, Griffin RJ.

PLoS One. 2015 Aug 26;10(8):e0135607. doi: 10.1371/journal.pone.0135607. eCollection 2015.

14.

Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluation.

Läppchen T, Dings RP, Rossin R, Simon JF, Visser TJ, Bakker M, Walhe P, van Mourik T, Donato K, van Beijnum JR, Griffioen AW, Lub J, Robillard MS, Mayo KH, Grüll H.

Eur J Med Chem. 2015 Jan 7;89:279-95. doi: 10.1016/j.ejmech.2014.10.048. Epub 2014 Oct 18.

PMID:
25462244
15.

Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa.

Dings RP, Haseman JR, Leslie DB, Luong M, Dunn DL, Mayo KH.

Biochim Biophys Acta. 2013 Jun;1830(6):3454-7. doi: 10.1016/j.bbagen.2013.02.002. Epub 2013 Feb 9.

16.

Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer.

Dings RP, Levine JI, Brown SG, Astorgues-Xerri L, MacDonald JR, Hoye TR, Raymond E, Mayo KH.

Invest New Drugs. 2013 Oct;31(5):1142-50. doi: 10.1007/s10637-013-9932-0. Epub 2013 Feb 8.

17.

Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1.

Dings RP, Kumar N, Miller MC, Loren M, Rangwala H, Hoye TR, Mayo KH.

J Pharmacol Exp Ther. 2013 Mar;344(3):589-99. doi: 10.1124/jpet.112.199646. Epub 2012 Dec 11.

18.

Microbeam radiation therapy alters vascular architecture and tumor oxygenation and is enhanced by a galectin-1 targeted anti-angiogenic peptide.

Griffin RJ, Koonce NA, Dings RP, Siegel E, Moros EG, Bräuer-Krisch E, Corry PM.

Radiat Res. 2012 Jun;177(6):804-12. Epub 2012 May 18.

19.

Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.

Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH.

J Med Chem. 2012 Jun 14;55(11):5121-9. doi: 10.1021/jm300014q. Epub 2012 May 30.

20.

Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells.

Song CW, Lee H, Dings RP, Williams B, Powers J, Santos TD, Choi BH, Park HJ.

Sci Rep. 2012;2:362. doi: 10.1038/srep00362. Epub 2012 Apr 12.

Supplemental Content

Loading ...
Support Center